A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma (CAINAS)
Primary Purpose
ASTHMA
Status
Completed
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
Formoterol/Budesonide
Foraseq
Sponsored by

About this trial
This is an interventional treatment trial for ASTHMA
Eligibility Criteria
Inclusion Criteria:
- Sign ICF (see Attachment A);
- Age ≥12 years old
- Diagnosis of mild to moderate persistent asthma, as per the ARIA classification, 35 with symptoms for at least 6 months, clinically stable for at least 1 month with ACQ-7 test34 (see Attachment D) < 3.0;
- Current use of inhaled corticosteroids (equivalent to beclometasone dipropionate 1000µg) associated or not to long-acting β2-adrenergics and relief medication (salbutamol or equivalent);
- Initial FEV1 of at least 50% of the normal value estimated.
- Serum cortisol evaluation within the normal values
Exclusion Criteria:
- Use of oral or parenteral corticosteroids within the last 3 months;
- Need of hospitalization due to asthma within the last 3 months;
- Active tabagism, defined as the use of cigarettes, pipe, cigar or any other type in any amount within the last 3 months;
- Severe co-morbidity, such as cardiovascular, renal, liver, neurologic, neoplastic, blood, infectious, dermatologic, neurologic, psychiatric or chronic respiratory diseases, other than asthma;
- Recent participation (<6 months) or planned participation, during this study, on other clinical trials involving drugs of any nature or under studies of any type of intervention for the asthma treatment;
- Intolerance or allergy to any of the compounds of the drugs evaluated on the study;
- Pregnancy or lactation;
- Chronic use of routine oral or intravenous β-blocker drugs, even ophthalmic solutions.
Sites / Locations
- Centro de Pesquisa Clínica Stelmach
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Formoterol/Budesonide
Foraseq
Arm Description
Outcomes
Primary Outcome Measures
The study primary endpoint will be the forced expiratory volume in 1 second (FEV1) at the final visit (FV) at each study arm.
Secondary Outcome Measures
Only one Score of asthma control questionnaire (ACQ-7) 34 at the end of the study.
Full Information
NCT ID
NCT01001364
First Posted
October 23, 2009
Last Updated
June 27, 2011
Sponsor
Eurofarma Laboratorios S.A.
1. Study Identification
Unique Protocol Identification Number
NCT01001364
Brief Title
A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma
Acronym
CAINAS
Official Title
A Phase III, Randomized, Open-Label, Non-Inferiority Comparative Study Between Foraseq Inhalation Capsules 12/200 µg And Formoterol/ Budesonide Inhalation Capsules 12/200 µg Eurofarma In Patients With Asthma
Study Type
Interventional
2. Study Status
Record Verification Date
June 2010
Overall Recruitment Status
Completed
Study Start Date
February 2010 (undefined)
Primary Completion Date
April 2011 (Actual)
Study Completion Date
April 2011 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Eurofarma Laboratorios S.A.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study primary objective is to compare the impact of two products containing budesonide and formoterol as individual capsules with inhalation powder for the pulmonary function of subjects with persistent asthma.
Detailed Description
This study primary objective is to compare the impact of two products containing budesonide and formoterol as individual capsules with inhalation powder for the pulmonary function of subjects with persistent asthma. This is a non-inferiority study, which hypothesis is that there is no difference on the pulmonary function measure between the groups studied at its end. Therefore, the study primary endpoint will be the forced expiratory volume in 1 second (FEV1) at the final visit (FV) at each study arm.
This study secondary objective is to compare the impact on the clinical control of two products containing budesonide and formoterol as individual capsules with inhalation powder in subjects with persistent asthma.
The secondary endpoints considered for this study are:
Score of asthma control questionnaire (ACQ-7) 34 at the end of the study ;
Peak of expiratory flow (PEF) throughout the study;
Symptoms score at the end of the study;
FEV1 throughout the study;
Treatment safety, including serum cortisol dosage;
Frequency of observed adverse events.
Some eligibility criteria:
Current use of inhaled corticosteroids (equivalent to beclometasone dipropionate 1000µg) associated or not to long-acting β2-adrenergics and relief medication (salbutamol or equivalent);
Diagnosis of mild to moderate persistent asthma, as per the ARIA classification, 35 with symptoms for at least 6 months, clinically stable for at least 1 month with ACQ-7 test34 (see Attachment D) < 3.0;
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ASTHMA
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
88 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Formoterol/Budesonide
Arm Type
Experimental
Arm Title
Foraseq
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Formoterol/Budesonide
Intervention Description
formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Foraseq
Intervention Description
formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
Primary Outcome Measure Information:
Title
The study primary endpoint will be the forced expiratory volume in 1 second (FEV1) at the final visit (FV) at each study arm.
Time Frame
4 months
Secondary Outcome Measure Information:
Title
Only one Score of asthma control questionnaire (ACQ-7) 34 at the end of the study.
Time Frame
4 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Sign ICF (see Attachment A);
Age ≥12 years old
Diagnosis of mild to moderate persistent asthma, as per the ARIA classification, 35 with symptoms for at least 6 months, clinically stable for at least 1 month with ACQ-7 test34 (see Attachment D) < 3.0;
Current use of inhaled corticosteroids (equivalent to beclometasone dipropionate 1000µg) associated or not to long-acting β2-adrenergics and relief medication (salbutamol or equivalent);
Initial FEV1 of at least 50% of the normal value estimated.
Serum cortisol evaluation within the normal values
Exclusion Criteria:
Use of oral or parenteral corticosteroids within the last 3 months;
Need of hospitalization due to asthma within the last 3 months;
Active tabagism, defined as the use of cigarettes, pipe, cigar or any other type in any amount within the last 3 months;
Severe co-morbidity, such as cardiovascular, renal, liver, neurologic, neoplastic, blood, infectious, dermatologic, neurologic, psychiatric or chronic respiratory diseases, other than asthma;
Recent participation (<6 months) or planned participation, during this study, on other clinical trials involving drugs of any nature or under studies of any type of intervention for the asthma treatment;
Intolerance or allergy to any of the compounds of the drugs evaluated on the study;
Pregnancy or lactation;
Chronic use of routine oral or intravenous β-blocker drugs, even ophthalmic solutions.
Facility Information:
Facility Name
Centro de Pesquisa Clínica Stelmach
City
São Paulo
State/Province
SP
ZIP/Postal Code
05437 010
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
A Comparative Study Between Foraseq And Formoterol/Budesonide Inhalation Capsules in Patients With Asthma
We'll reach out to this number within 24 hrs